Crimean-Congo Hemorrhagic Fever among Health Care Workers, Turkey

Aysel Kocagul Celikbas, Başak Dokuzoğuz, Nurcam Baykam, Sebnem Eren Gok, Mustafa Necati Eroğlu, Kenan Midilli, Herve Zeller, and Onder Ergonul

We investigated 9 cases of Crimean-Congo hemorrhagic fever (1 fatal, 2 asymptomatic) among health care workers in Turkey. Needlestick injuries were reported for 4 workers. Eight received ribavirin. In addition to standard precautions, airborne infection isolation precautions are essential during aerosol-generating procedures. For postexposure prophylaxis and therapy, ribavirin should be given.

Crimean-Congo hemorrhagic fever (CCHF) has been described from Africa, Asia, southeastern Europe, and the Middle East (1). The CCHF virus (CCHFV) belongs to the family Bunyaviridae, genus Nairovirus, and causes severe disease in humans; the reported case-fatality rate is 3%-30% (1). Humans become infected through the bites of ticks, contact with infected patients’ body fluids, or contact with blood or tissues from viremic livestock. Health care workers (HCWs) are at occupational risk for CCHFV infection. Health care–related CCHFV infections have been reported in Pakistan (2–5), the United Arab Emirates (6), South Africa (7), Iran (8), India (9), Tajikistan (10), and Turkey (11). We describe the outcomes of 9 HCWs in Turkey who had occupational exposure to CCHFV.

The Cases

The 9 HCWs and all CCHF patients under their care were admitted to the Infectious Diseases and Clinical Microbiology clinic (IDCM) of Ankara Numune Education and Research Hospital (Ankara, Turkey) during 2004–2011 with confirmed CCHF. All 9 HCWs were aware of possible or confirmed CCHFV infection in their patients. During this period, ≈7,000 confirmed CCHF cases were recorded in Turkey; nearly 300 of these patients were hospitalized in IDCM. Acute- and convalescent-phase serum samples from the index patients were sent to the national reference laboratory of Turkey. CCHFV infection was confirmed through IgM positivity by ELISA and/or positive PCR results for CCHFV in blood. After episode 1, the HCWs’ serum samples were sent to the Pasteur Institute (Lyon, France) for contact tracing. The HCWs’ infections were scored according to a severity score index (12). In episode 3, to investigate the source of infection, molecular techniques were used. Oral ribavirin for treatment was administered at the dosage recommended by the World Health Organization (4 g/d for 4 d, 2.4 g/d for 6 d), and for prophylaxis (2g/4×/d for 7 d). The index patients and the HCWs were given erythrocyte, fresh frozen plasma, and total blood preparations depending on their homeostasis.

Episode 1

In 2005, CCHFV infection was diagnosed in a woman on the day of delivery by cesarean section. She was transferred to IDCM, and her baby was transferred to the newborn service at the Dr. Sami Ulus Children’s Hospital (Ankara, Turkey). A nurse in IDCM, who had fever and myalgia, was later found to have CCHFV infection (Table 1). Transmission was related to the improper use of gloves during the care of the mother’s surgical wound. The mother recovered, but the infant died 5 days after birth. A nurse in the neonatal clinic in the children’s hospital also acquired CCHFV infection, which was attributed to the intubation and aspiration of bloody secretions from the baby without proper use of gloves and mask. For both HCWs, the incubation period was 2 days. The first HCW was given ribavirin at symptom onset. The second nurse’s illness was mild; because she had a potential for getting pregnant, ribavirin was not started. Both nurses recovered completely (Table 2).

After this episode, the index patient’s contacts were traced. Serum samples from 37 HCWs at IDCM and the obstetrics and newborn clinics at the children’s hospital who were at risk for infection were investigated for CCHF. In addition to the 2 nurses, 2 nurses from the neonatal clinic were CCHF IgM positive but were asymptomatic.

Episode 2

In 2006, a nurse received a needlestick injury during a phlebotomy of a CCHFV-infected patient. She was using gloves but no gown, and the needle stuck to her forearm. The infected patient died. The nurse’s symptoms began 2 days after the incident, and she was transferred to IDCM 4 days after the incident. At admission, her severity score index was high. She had ecchymosis, epistaxis, hematemesis, melena, vaginal bleeding, and somnolence (Table 1). She received oral ribavirin 5 days after the incident, which possibly had limited effect because her illness already had progressed to confusion and gastrointestinal bleeding. She died on the second day after hospital admission.
was observed between the patient and the HCWs, but the sure. Ribavirin was started at symptom onset. No contact fever, malaise, and myalgia developed 2–5 days after expo-
tact with the patient’s bloody secretions. For the 3 residents,-
- resident resuscitated the patient without apparent direct con
- face-to-face contact with the patient. The infectious diseases head mirror without using gloves, although he was not in
- other otorhinolaryngology resident handled and cleaned a
dent performed nasal tamponade. After the intervention, the
- ment during the intervention. One otorhinolaryngology resi
- dent and 2 otorhinolaryngology residents acquired CCHFV

He died 3 days after admission. One infectious diseases resi
- hematemesis, melena, and intraalveolar bleeding. The

In 2008, a patient with CCHFV infection and a high vi
-功力 load (10⁸ copies/mL) was hospitalized with hemoptysis, hematemesis, melena, epistaxis, and intraalveolar bleeding. He died 3 days after admission. One infectious diseases resi
- dent and 2 otorhinolaryngology residents acquired CCHFV infection. All HCWs had worn personal protective equip
- during the intervention. One otorhinolaryngology resi
- dent performed nasal tamponade. After the intervention, the
- other otorhinolaryngology resident handled and cleaned a
- mirror without using gloves, although he was not in
- face-to-face contact with the patient. The infectious diseases resident resuscitated the patient without apparent direct con
- the patient’s bloody secretions. For the 3 residents, fever, malaise, and myalgia developed 2–5 days after exposure. Ribavirin was started at symptom onset. No contact was observed between the patient and the HCWs, but the

**Episode 3**

In 2008, a patient with CCHFV infection and a high vi
-功力 load (10⁸ copies/mL) was hospitalized with hemoptysis, hematemesis, melena, epistaxis, and intraalveolar bleeding. He died 3 days after admission. One infectious diseases resi
- dent and 2 otorhinolaryngology residents acquired CCHFV infection. All HCWs had worn personal protective equip
- during the intervention. One otorhinolaryngology resi
- dent performed nasal tamponade. After the intervention, the
- other otorhinolaryngology resident handled and cleaned a
- mirror without using gloves, although he was not in
- face-to-face contact with the patient. The infectious diseases resident resuscitated the patient without apparent direct con
- the patient’s bloody secretions. For the 3 residents, fever, malaise, and myalgia developed 2–5 days after exposure. Ribavirin was started at symptom onset. No contact was observed between the patient and the HCWs, but the

RNA sequences from the patients and HCWs were identical by molecular techniques. All of the HCWs recovered.

The transmission of CCHFV could have resulted from indi
- contact with contaminated devices, such as the head mirror; the improper removal of gowns, masks, gloves; inadequate hand hygiene; or failure to use N95 masks during aerosolizing procedures. During the proce
- dures that could generate aerosols, HCWs should wear an

**Episode 4**

In 2008, a phlebotomist working in a children’s hospital had a needlestick injury during phlebotomy of a CCHFV-infected child. He was hospitalized 1 day after symptom onset, and ribavirin was started. His severity score index was moderate, and he recovered.

**Table 1. Clinical and laboratory findings of HCWs in whom Crimean-Congo hemorrhagic fever developed after occupational exposure, Turkey, 2004–2011**

| HCW, outcome | Body temperature, °C | Bleeding | Leukocytes/mm³ | Platelets/mm³ | AST | ALT | APTT | Fibrinogen | SSI |
|--------------|----------------------|----------|---------------|---------------|-----|-----|------|------------|-----|
| 1, survived  | 38.5                 | No       | 800           | 42,000        | 425 | 346 | 44   | 225        | Moderate |
| 2, survived  | 37.2                 | No       | 1100          | 53,000        | 145 | 81  | 43   | 270        | Mild    |
| 3, died      | 40.5                 | Ecchymosis, hematemesis, melena, hematuria | 11,100        | 40,000        | 251 | 277 | 90   | 171        | Severe  |
| 4, survived  | 40.5                 | No       | 2,900         | 78,000        | 150 | 110 | 37.4 | 250        | Mild    |
| 5, survived  | 39                   | Epistaxis| 1,800         | 58,000        | 167 | 129 | 64   | 218        | Moderate |
| 6, survived  | 40.5                 | No       | 1,800         | 44,000        | 123 | 216 | 40.5 | 165        | Moderate |
| 7, survived  | 39.1                 | No       | 3,100         | 13,000        | 418 | 132 | 40.9 | 170        | Moderate |

*HCW, health care worker; AST, aspartate aminotransferase; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; SSI, severity score index.
†Reference values: leukocytes, 4,000–11,000/mm³; platelets, 150,000–450,000/mm³; AST, <50 IU/L; ALT, <50 IU/L; APTT, 24–36 sec; fibrinogen, 200–400 mg/dL.

**Table 2. Demographic features of HCWs with occupational exposure to Crimean-Congo hemorrhagic fever virus, Turkey, 2004–2011**

| Episode, outcome† | HCW age, y/sex/profession | Procedure | Transmission route | Ribavirin for postexposure prophylaxis | Ribavirin for therapy (d after symptom onset) | Fatal |
|-------------------|-----------------------------|-----------|-------------------|---------------------------------------|-----------------------------------------------|-------|
| Episode 1; survived, her baby died | 36/M/nurse | Wound care | Contact with surgical wound without protective equipment | No | Yes (0) | No |
| 31/F/nurse | Intubation, aspiration | Aerosol and droplet and contact without protective equipment | No | No | No |
| Episode 2; died | 28/F/nurse | Phlebotomy | Needlestick | No | Yes (3) | Yes |
| Episode 3; died | 41/M/physician | Resuscitation | Aerosol and droplet | – | Yes (0) | No |
| 26/M/physician | Nasal tamponade | Indirect contact | – | Yes (0) | No |
| 29/M/physician | Nasal tamponade | Indirect contact | – | Yes (0) | No |
| Episode 4; survived | 30/M/nurse | Phlebotomy | Needlestick | No | Yes (1) | No |
| Episode 5; survived | 30/F/nurse | Phlebotomy | Needlestick | Yes | – | No |
| Episode 6; survived | 24/F/physician | Phlebotomy | Needlestick | Yes | – | No |

†Outcome for the index case-patient in each episode.
Episodes 5 and 6

A nurse in 2007 and a pediatric resident in 2008 incurred needlestick injuries during phlebotomy of a CCHFV-infected patient. Postexposure prophylaxis with ribavirin was started immediately after the injuries, and no infections developed.

Conclusions

Six of the 9 CCHF-infected HCWs reported here had histories of needlestick injuries or contact with contaminated blood without adequate barrier precautions. An integrated strategy for controlling accidental exposure to body fluids was developed to protect HCWs against CCHFV infection. All personnel, including cleaning staff in health care units on all shifts were informed and trained about the transmission risks, protection, and clinical symptoms of CCHF (13). The standard, contact, and droplet precautions were usually sufficient to protect against CCHFV infection during the routine care of CCHF patients. In addition to the practices of previous years, the airborne infection isolation precautions during aerosol-generating procedures were performed. The number of HCWs caring for patients with severe CCHF was limited. After all of these measures were enforced, occupational CCHFV infection did not occur in IDCAM.

Ribavirin is an effective treatment for CCHFV infection (12) and beneficial for postexposure prophylaxis (13,15). Therapy should be started as early as possible. In the 2 HCWs reported here who received ribavirin for postexposure prophylaxis, no symptoms developed; similar reports of severe CCHF were limited. After all of these measures were enforced, occupational CCHFV infection did not occur in IDCAM.

Dr Celikbas is an infectious disease and clinical microbiology specialist at the Ankara Numune Training and Education Hospital in Ankara, Turkey. Her primary research interests include emerging infections and brucellosis.

References

1. Ergonul O. Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol. 2012;2:215–20. http://dx.doi.org/10.1016/j.coviro.2012.03.001
2. Athar MN, Khalid MA, Ahmad AM, Bashir N, Baqri HZ, Ahmad M, et al. Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002: contact tracing and risk assessment. Am J Trop Med Hyg. 2005;72:471–3.
3. Alfar A, Luby S, Ahmed AJ, Zaidi N, Khan AJ, Mirza S, et al. Outbreak of Crimean-Congo haemorrhagic fever in Quetta, Pakistan: contact tracing and risk assessment. Trop Med Int Health. 1998;3:878–82. http://dx.doi.org/10.1046/j.1365-3156.1998.00318.x
4. Fisher-Hoch SP, McCormick JB, Swanepoil R, Van Middelkoop A, Harvey S, Kustner HG. Risk of human infections with Crimean-Congo hemorrhagic fever virus in a South African rural community. Am J Trop Med Hyg. 1992;47:337–45.
5. Burney MI, Ghafoor A, Saleen M, Webb PA, Casals J. Nosocomial outbreak of viral hemorrhagic fever caused by Crimean hemorrhagic fever–Congo virus in Pakistan, January 1976. Am J Trop Med Hyg. 1980;29:941–7.
6. Suleiman MN, Muscat-Baron JM, Harries JR, Satti AG, Platt GS, Bowen ET, et al. Congo/Crimean haemorrhagic fever in Dubai. An outbreak at the Rashid Hospital. Lancet. 1980;2:939–41. http://dx.doi.org/10.1016/S0140-6736(80)92103-0
7. van de Wal BW, Joubert JR, van Eeden PJ, King JB. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures. S Afr Med J. 1985;68:729–32.
8. Mardani M, Rahnavardi M, Rajaeenejad M, Naini KH, Chinkar S, Pourmalek F, et al. Crimean-Congo hemorrhagic fever among health care workers in Iran: a seroprevalence study in two endemic regions. Am J Trop Med Hyg. 2007;76:443–45.
9. Mishra AC, Mehta M, Mourya DT, Gandhi S. Crimean-Congo haemorrhagic fever in India. Lancet. 2011;378:372. http://dx.doi.org/10.1016/S0140-6736(11)60680-6
10. Tishkova FH, Belobrova EA, Valikhodzhaev M, Atkinson B, Hewson R, Mullolonova M. Crimean-Congo hemorrhagic fever in Tajikistan. Vector Borne Zoonotic Dis. 2012;12:722–6. http://dx.doi.org/10.1089/vbz.2011.0769
11. Tütüncü EE, Gurbuz Y, Ozturk B, Kuscu F, Sencan I. Crimean Congo hemorrhagic fever, precautions and ribavirin prophylaxis: a case report. Scand J Infect Dis. 2009;41:378–80. http://dx.doi.org/10.1080/00365540902882434
12. Dokuzoguz B, Celikbas A, Eren S, Baykam N, Eroglu MN, Ergonul O. Severity scoring index for Crimean Congo hemorrhagic fever virus infection and the impact of ribavirin and corticosteroids on fatality. Clin Infect Dis. 2013;57:1270–4. http://dx.doi.org/10.1093/cid/cit527
13. Tarantola A, Ergonul O, Tattevin P. Estimates and prevention of Crimean Congo hemorrhagic fever risks for health care workers. In: Ergonul O, Whitehouse CA, editors. Crimean-Congo hemorrhagic fever: a global perspective. Dordrecht (the Netherlands): Springer; 2007. p. 281–94.
14. Duh D, Saksida A, Petrovec M, Ahmeti S, Dedushaj I, Panning M, et al. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg Infect Dis. 2007;13:1769–72. http://dx.doi.org/10.3201/eid1311.070222
15. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res. 2008;78:125–31. http://dx.doi.org/10.1016/j.antiviral.2007.11.002

Address for correspondence: Onder Ergonul, Koç University, School of Medicine, Infectious Diseases Department, Istanbul, Turkey; email: oergonul@ku.edu.tr

CME

Sign up to receive email announcements when a new article is available.

Get an online subscription at wwwnc.cdc.gov/eid/subscribe.htm